Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA. Isaacs C, et al. Among authors: overmoyer b. J Clin Oncol. 1997 Nov;15(11):3368-77. doi: 10.1200/JCO.1997.15.11.3368. J Clin Oncol. 1997. PMID: 9363868 Clinical Trial.
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Nakhlis F, et al. Among authors: overmoyer b. Breast Cancer Res Treat. 2024 Apr;204(2):289-297. doi: 10.1007/s10549-023-07195-5. Epub 2023 Dec 28. Breast Cancer Res Treat. 2024. PMID: 38155272
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, Eichler A, Heist RS, Krop I, Lawrence D, Ligibel J, Tolaney S, Mayer E, Winer E, Bent B, de Sauvage MA, Ijad N, Larson JM, Marion B, Nason S, Murthy N, Ratcliff S, Summers EJ, Mahar M, Shih HA, Oh K, Cahill DP, Gerstner ER, Sullivan RJ. Brastianos PK, et al. Among authors: overmoyer b. Nat Med. 2023 Jul;29(7):1728-1737. doi: 10.1038/s41591-023-02392-7. Epub 2023 Jun 2. Nat Med. 2023. PMID: 37268724 Free PMC article. Clinical Trial.
Copy Number Variation in Inflammatory Breast Cancer.
Hazra A, O'Hara A, Polyak K, Nakhlis F, Harrison BT, Giordano A, Overmoyer B, Lynce F. Hazra A, et al. Among authors: overmoyer b. Cells. 2023 Apr 4;12(7):1086. doi: 10.3390/cells12071086. Cells. 2023. PMID: 37048158 Free PMC article.
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
Garrido-Castro AC, Regan MM, Niman SM, Nakhlis F, Remolano C, Rosenbluth JM, Block C, Warren LE, Bellon JR, Yeh E, Harrison BT, Troll E, Lin NU, Tolaney SM, Overmoyer B, Lynce F. Garrido-Castro AC, et al. Among authors: overmoyer b. NPJ Breast Cancer. 2023 Jun 2;9(1):50. doi: 10.1038/s41523-023-00555-w. NPJ Breast Cancer. 2023. PMID: 37268625 Free PMC article.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Burstein HJ, et al. Among authors: overmoyer b. J Clin Oncol. 2003 Aug 1;21(15):2889-95. doi: 10.1200/JCO.2003.02.018. J Clin Oncol. 2003. PMID: 12885806 Clinical Trial.
113 results